Every FDA-approved neurotoxin and dermal filler an injector buys is a prescription product. FDA says botulinum toxin products are only available with a prescription from a licensed health care professional, and that the only FDA-approved dermal fillers are supplied by prescription for injection by a licensed professional. So before an ad runs, two answers have to hold up: who may inject in your state, and where the product comes from.
California. The Medical Board of California says physicians may inject Botox or direct registered nurses or physician assistants to do it under their supervision, and that no unlicensed person, such as a medical assistant, may inject it. A nurse may not employ or contract with a physician for supervision, and the board says there is no such thing as a “sponsoring physician.” To offer these treatments at all, the business has to be organized as a medical practice or professional medical corporation owned by physicians, with a physician holding most of the shares. The supervising physician need not be on site but must be immediately reachable.
Texas. Under section 157.001 of the Occupations Code, a physician may hand a medical act to a qualified, properly trained person working under that physician’s supervision, and the physician stays responsible for it. Nursing board rules sit on top of that statute, so a Texas nurse injector business should confirm its arrangement with counsel before it advertises.
Florida. The statute defining registered nurse practice includes administering medications and treatments as prescribed or authorized by a practitioner licensed to prescribe them, so the prescriber is part of the structure there as well.
New York. Federal prosecutors charged a Manhattan medical spa operator who allegedly shipped counterfeit Botox from Asia and injected it without the license New York requires, according to the FDA’s Office of Criminal Investigations.
The product. FDA’s April 2024 alert on counterfeit Botox reminds providers that federal law requires them to buy prescription drugs only from authorized sources. The CDC advisory that followed counted 22 people in 11 states with adverse effects, and every one reported injections by unlicensed or untrained people or in non-healthcare settings, including homes or spas. In November 2025 FDA sent 18 warning letters to websites illegally marketing unapproved botulinum toxin products.
What this means for the marketing: name the medical director, show each injector’s license type, say the product is FDA-approved and comes from an authorized distributor when that is true, and settle the structure before paying for a single click. In California, a misleading ad earns a direction from the board to change it. An illegal practice is told to stop.
